Ryan M. Walsh
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryan M. Walsh.
Nature | 2009
Jochen Utikal; Jose M. Polo; Matthias Stadtfeld; Nimet Maherali; Warakorn Kulalert; Ryan M. Walsh; Adam Khalil; James G. Rheinwald
The overexpression of defined transcription factors in somatic cells results in their reprogramming into induced pluripotent stem (iPS) cells. The extremely low efficiency and slow kinetics of in vitro reprogramming suggest that further rare events are required to generate iPS cells. The nature and identity of these events, however, remain elusive. We noticed that the reprogramming potential of primary murine fibroblasts into iPS cells decreases after serial passaging and the concomitant onset of senescence. Consistent with the notion that loss of replicative potential provides a barrier for reprogramming, here we show that cells with low endogenous p19Arf (encoded by the Ink4a/Arf locus, also known as Cdkn2a locus) protein levels and immortal fibroblasts deficient in components of the Arf–Trp53 pathway yield iPS cell colonies with up to threefold faster kinetics and at a significantly higher efficiency than wild-type cells, endowing almost every somatic cell with the potential to form iPS cells. Notably, the acute genetic ablation of Trp53 (also known as p53) in cellular subpopulations that normally fail to reprogram rescues their ability to produce iPS cells. Our results show that the acquisition of immortality is a crucial and rate-limiting step towards the establishment of a pluripotent state in somatic cells and underscore the similarities between induced pluripotency and tumorigenesis.
Cell | 2012
Jose M. Polo; Endre Anderssen; Ryan M. Walsh; Benjamin A. Schwarz; Christian M. Nefzger; Sue Mei Lim; Marti Borkent; Effie Apostolou; Sara Alaei; Jennifer Cloutier; Ori Bar-Nur; Sihem Cheloufi; Matthias Stadtfeld; Maria E. Figueroa; Daisy Robinton; Sridaran Natesan; Ari Melnick; Jinfang Zhu; Sridhar Ramaswamy
Factor-induced reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is inefficient, complicating mechanistic studies. Here, we examined defined intermediate cell populations poised to becoming iPSCs by genome-wide analyses. We show that induced pluripotency elicits two transcriptional waves, which are driven by c-Myc/Klf4 (first wave) and Oct4/Sox2/Klf4 (second wave). Cells that become refractory to reprogramming activate the first but fail to initiate the second transcriptional wave and can be rescued by elevated expression of all four factors. The establishment of bivalent domains occurs gradually after the first wave, whereas changes in DNA methylation take place after the second wave when cells acquire stable pluripotency. This integrative analysis allowed us to identify genes that act as roadblocks during reprogramming and surface markers that further enrich for cells prone to forming iPSCs. Collectively, our data offer new mechanistic insights into the nature and sequence of molecular events inherent to cellular reprogramming.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Masafumi Toyoshima; Heather L. Howie; Maki Imakura; Ryan M. Walsh; James Annis; Aaron N. Chang; Jason Frazier; B. Nelson Chau; Andrey Loboda; Peter S. Linsley; Michele A. Cleary; Julie R. Park; Carla Grandori
MYC oncogene family members are broadly implicated in human cancers, yet are considered “undruggable” as they encode transcription factors. MYC also carries out essential functions in proliferative tissues, suggesting that its inhibition could cause severe side effects. We elected to identify synthetic lethal interactions with c-MYC overexpression (MYC-SL) in a collection of ∼3,300 druggable genes, using high-throughput siRNA screening. Of 49 genes selected for follow-up, 48 were confirmed by independent retesting and approximately one-third selectively induced accumulation of DNA damage, consistent with enrichment in DNA-repair genes by functional annotation. In addition, genes involved in histone acetylation and transcriptional elongation, such as TRRAP and BRD4, were identified, indicating that the screen revealed known MYC-associated pathways. For in vivo validation we selected CSNK1e, a kinase whose expression correlated with MYCN amplification in neuroblastoma (an established MYC-driven cancer). Using RNAi and available small-molecule inhibitors, we confirmed that inhibition of CSNK1e halted growth of MYCN-amplified neuroblastoma xenografts. CSNK1e had previously been implicated in the regulation of developmental pathways and circadian rhythms, whereas our data provide a previously unknown link with oncogenic MYC. Furthermore, expression of CSNK1e correlated with c-MYC and its transcriptional signature in other human cancers, indicating potential broad therapeutic implications of targeting CSNK1e function. In summary, through a functional genomics approach, pathways essential in the context of oncogenic MYC but not to normal cells were identified, thus revealing a rich therapeutic space linked to a previously “undruggable” oncogene.
Molecular Cell | 2010
Joshua C. Black; Andrew Allen; Capucine Van Rechem; Emily Forbes; Michelle S. Longworth; Katrin Tschöp; Claire A. Rinehart; Jonathan Quiton; Ryan M. Walsh; Andrea Smallwood; Nicholas J. Dyson; Johnathan R. Whetstine
The KDM4/JMJD2 family of histone demethylases is amplified in human cancers. However, little is known about their physiologic or tumorigenic roles. We have identified a conserved and unappreciated role for the JMJD2A/KDM4A H3K9/36 tridemethylase in cell cycle progression. We demonstrate that JMJD2A protein levels are regulated in a cell cycle-dependent manner and that JMJD2A overexpression increased chromatin accessibility, S phase progression, and altered replication timing of specific genomic loci. These phenotypes depended on JMJD2A enzymatic activity. Strikingly, depletion of the only C. elegans homolog, JMJD-2, slowed DNA replication and increased ATR/p53-dependent apoptosis. Importantly, overexpression of HP1γ antagonized JMJD2A-dependent progression through S phase, and depletion of HPL-2 rescued the DNA replication-related phenotypes in jmjd-2(-/-) animals. Our findings describe a highly conserved model whereby JMJD2A regulates DNA replication by antagonizing HP1γ and controlling chromatin accessibility.
Nature Cell Biology | 2015
Jean-Pierre Etchegaray; Lukas Chavez; Yun Huang; Kenneth N. Ross; Jiho Choi; Barbara Martinez-Pastor; Ryan M. Walsh; Cesar A. Sommer; Matthias Lienhard; Adrianne D. Gladden; Sita Kugel; Dafne M. Silberman; Sridhar Ramaswamy; Gustavo Mostoslavsky; Alon Goren; Anjana Rao; Raul Mostoslavsky
How embryonic stem cells (ESCs) commit to specific cell lineages and yield all cell types of a fully formed organism remains a major question. ESC differentiation is accompanied by large-scale histone and DNA modifications, but the relations between these epigenetic categories are not understood. Here we demonstrate the interplay between the histone deacetylase sirtuin 6 (SIRT6) and the ten-eleven translocation enzymes (TETs). SIRT6 targets acetylated histone H3 at Lys 9 and 56 (H3K9ac and H3K56ac), while TETs convert 5-methylcytosine into 5-hydroxymethylcytosine (5hmC). ESCs derived from Sirt6 knockout (S6KO) mice are skewed towards neuroectoderm development. This phenotype involves derepression of OCT4, SOX2 and NANOG, which causes an upregulation of TET-dependent production of 5hmC. Genome-wide analysis revealed neural genes marked with 5hmC in S6KO ESCs, thereby implicating TET enzymes in the neuroectoderm-skewed differentiation phenotype. We demonstrate that SIRT6 functions as a chromatin regulator safeguarding the balance between pluripotency and differentiation through Tet-mediated production of 5hmC.
Nature Methods | 2014
Ori Bar-Nur; Justin Brumbaugh; Cassandra Verheul; Effie Apostolou; Iulian Pruteanu-Malinici; Ryan M. Walsh; Sridhar Ramaswamy
The reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) upon overexpression of OCT4, KLF4, SOX2 and c-MYC (OKSM) provides a powerful system to interrogate basic mechanisms of cell fate change. However, iPSC formation with standard methods is typically protracted and inefficient, resulting in heterogeneous cell populations. We show that exposure of OKSM-expressing cells to both ascorbic acid and a GSK3-β inhibitor (AGi) facilitates more synchronous and rapid iPSC formation from several mouse cell types. AGi treatment restored the ability of refractory cell populations to yield iPSC colonies, and it attenuated the activation of developmental regulators commonly observed during the reprogramming process. Moreover, AGi supplementation gave rise to chimera-competent iPSCs after as little as 48 h of OKSM expression. Our results offer a simple modification to the reprogramming protocol, facilitating iPSC induction at unparalleled efficiencies and enabling dissection of the underlying mechanisms in more homogeneous cell populations.
Nature | 2017
Jiho Choi; Aaron J. Huebner; Kendell Clement; Ryan M. Walsh; Andrej J. Savol; Kaixuan Lin; Hongcang Gu; Bruno Di Stefano; Justin Brumbaugh; Sang Yong Kim; Jafar Sharif; Christopher Rose; Arman Mohammad; Junko Odajima; Jean Charron; Toshihiro Shioda; Andreas Gnirke; Steven P. Gygi; Haruhiko Koseki; Ruslan I. Sadreyev; Andrew Xiao; Alexander Meissner
Concomitant activation of the Wnt pathway and suppression of Mapk signalling by two small molecule inhibitors (2i) in the presence of leukaemia inhibitory factor (LIF) (hereafter termed 2i/L) induces a naive state in mouse embryonic stem (ES) cells that resembles the inner cell mass (ICM) of the pre-implantation embryo. Since the ICM exists only transiently in vivo, it remains unclear how sustained propagation of naive ES cells in vitro affects their stability and functionality. Here we show that prolonged culture of male mouse ES cells in 2i/L results in irreversible epigenetic and genomic changes that impair their developmental potential. Furthermore, we find that female ES cells cultured in conventional serum plus LIF medium phenocopy male ES cells cultured in 2i/L. Mechanistically, we demonstrate that the inhibition of Mek1/2 is predominantly responsible for these effects, in part through the downregulation of DNA methyltransferases and their cofactors. Finally, we show that replacement of the Mek1/2 inhibitor with a Src inhibitor preserves the epigenetic and genomic integrity as well as the developmental potential of ES cells. Taken together, our data suggest that, although short-term suppression of Mek1/2 in ES cells helps to maintain an ICM-like epigenetic state, prolonged suppression results in irreversible changes that compromise their developmental potential.
Proceedings of the National Academy of Sciences of the United States of America | 2013
Ryan M. Walsh
Targeted genome engineering has been instrumental for the study of biological processes, and it holds great promise for the treatment of disease. Historically, gene targeting by homologous recombination has been the preferred method to modify specific genes in mouse and human cells (Fig. 1). However, this approach is hampered by low efficiency, the requirement for drug selection to detect targeted cells, and the limited number of cell types and organisms amenable to the method. To overcome these limitations, technologies based on sequence-specific zinc finger (ZF) and transcription activator-like effector (TALE) proteins have been developed. These proteins can be engineered to theoretically recognize any DNA sequence in the genome. When fused to a nuclease domain and assembled in pairs flanking a target site of interest, ZF and TALE nucleases (ZFNs and TALENs) will introduce double-strand breaks (DSBs) on DNA. DSBs serve as substrates for nonhomologous end joining (NHEJ) or homology-directed repair (HDR), which in turn facilitate the engineering of targeted mutations, repair of endogenous mutations, or introduction of transgenic DNA elements. The clustered, regularly interspaced, short palindromic repeat (CRISPR)-CRISPR-associated (Cas) system represents the latest addition to this arsenal of tools for site-specific genome engineering (see below). Although each of these three gene modification approaches has advantages and disadvantages (Fig. 1), the pace and ease with which the CRISPR-Cas systems have been adapted to modify genes in different cell types and organisms suggests that it may very well become the new method of choice for genome engineering. In PNAS, Hou et al. introduce a unique variant of the Cas9 enzyme (1), which provides additional flexibility and specificity to the CRISPR system and to genome-modifying tools in general.
Cell Stem Cell | 2017
Jiho Choi; Kendell Clement; Aaron J. Huebner; Jamie Webster; Christopher M. Rose; Justin Brumbaugh; Ryan M. Walsh; Soohyun Lee; Andrej J. Savol; Jean-Pierre Etchegaray; Hongcang Gu; Patrick Boyle; Ulrich Elling; Raul Mostoslavsky; Ruslan I. Sadreyev; Peter J. Park; Steven P. Gygi; Alexander Meissner
Blastocyst-derived embryonic stem cells (ESCs) and gonad-derived embryonic germ cells (EGCs) represent two classic types of pluripotent cell lines, yet their molecular equivalence remains incompletely understood. Here, we compare genome-wide methylation patterns between isogenic ESC and EGC lines to define epigenetic similarities and differences. Surprisingly, we find that sex rather than cell type drives methylation patterns in ESCs and EGCs. Cell fusion experiments further reveal that the ratio of X chromosomes to autosomes dictates methylation levels, with female hybrids being hypomethylated and male hybrids being hypermethylated. We show that the X-linked MAPK phosphatase DUSP9 is upregulated in female compared to male ESCs, and its heterozygous loss in female ESCs leads to male-like methylation levels. However, male and female blastocysts are similarly hypomethylated, indicating that sex-specific methylation differences arise in culture. Collectively, our data demonstrate the epigenetic similarity of sex-matched ESCs and EGCs and identify DUSP9 as a regulator of female-specific hypomethylation.
Nature Communications | 2017
Ryan M. Walsh; Erica Y. Shen; Rosemary C. Bagot; Anthony Anselmo; Yan Jiang; Behnam Javidfar; Gregory Wojtkiewicz; Jennifer Cloutier; John W. Chen; Ruslan I. Sadreyev; Eric J. Nestler; Schahram Akbarian
PHF8 is a histone demethylase with specificity for repressive modifications. While mutations of PHF8 have been associated with cognitive defects and cleft lip/palate, its role in mammalian development and physiology remains unexplored. Here, we have generated a Phf8 knockout allele in mice to examine the consequences of Phf8 loss for development and behaviour. Phf8 deficient mice neither display obvious developmental defects nor signs of cognitive impairment. However, we report a striking resiliency to stress-induced anxiety- and depression-like behaviour on loss of Phf8. We further observe misregulation of serotonin signalling within the prefrontal cortex of Phf8 deficient mice and identify the serotonin receptors Htr1a and Htr2a as direct targets of PHF8. Our results clarify the functional role of Phf8 in mammalian development and behaviour and establish a direct link between Phf8 expression and serotonin signalling, identifying this histone demethylase as a potential target for the treatment of anxiety and depression.